TXG (10x Genomics) 3-Year RORE % : -55.68% (As of Mar. 2026)


TXG 10x Genomics Inc TXG
58 GF Score
Price $37.48
GF Value $18.95
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is 10x Genomics 3-Year RORE %?

10x Genomics TXG -0.98% 58 3-Year RORE % is -55.68 as of Mar. 2026. GuruFocus rates TXG with a GF Score™ of 58/100 and a GF Value™ of $18.95 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 605 Healthcare Providers & Services companies, 10x Genomics ranks worse than 83.31% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. 10x Genomics's 3-Year RORE % for the quarter that ended in Mar. 2026 was -55.68%.

The industry rank for 10x Genomics's 3-Year RORE % or its related term are showing as below:

TXG's 3-Year RORE % is ranked worse than
83.31% of 605 companies
in the Healthcare Providers & Services industry
Industry Median: 0.07 vs TXG: -55.68

10x Genomics  (NAS:TXG) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


10x Genomics 3-Year RORE % Related Terms


10x Genomics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for 10x Genomics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

10x Genomics 3-Year RORE % Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only -0.66 -51.54 39.66 0.97 -45.05

10x Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.55 -18.76 -31.77 -45.05 -55.68

TXG vs DOCS, WAY, PRVA: 3-Year RORE % Comparison

For the Health Information Services subindustry, 10x Genomics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


10x Genomics 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where 10x Genomics's 3-Year RORE % falls into.


TXG
58GF Score
10x Genomics Inc TXG
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

10x Genomics 3-Year RORE % Calculation

10x Genomics's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.17--2.23 )/( -3.7-0 )
=2.06/-3.7
=-55.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -55.68 mean?
10x Genomics (TXG) has a 3-Year RORE % of -55.68 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #504 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 83.3%.
Is 10x Genomics' 3-Year RORE % too high?
10x Genomics' current 3-Year RORE % is -55.68. Based on the distribution chart, 10x Genomics ranks #504 out of 605 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' 3-Year RORE % compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #504 out of 605 companies for 3-Year RORE %. This places 10x Genomics in the lower half of its industry. The industry median 3-Year RORE % is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.07, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current 3-Year RORE % is -55.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.95, compared to a current price of $37.48 — trading 97.8% above its estimated fair value. The current 3-Year RORE % is -55.68. 10x Genomics' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For 10x Genomics (TXG), the current 3-Year RORE % is -55.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 10x Genomics (TXG) Overvalued in 2026?

Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued. The current stock price of $37.48 is trading 97.8% above its estimated GF Value™ of $18.95. GuruFocus considers 10x Genomics to be Significantly Overvalued.

Key valuation signals for TXG:

  • 3-Year RORE %: -55.68
  • GF Value™: $18.95 vs. price of $37.48 (97.8% above fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


10x Genomics Business Description

Other Exchanges 0A88:UK1KJ:Germany
Address 6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
58GF Score

Get the complete analysis for TXG

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.48
Price
$18.95
GF Value